1. Home
  2. CRDL vs SBI Comparison

CRDL vs SBI Comparison

Compare CRDL & SBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDL
  • SBI
  • Stock Information
  • Founded
  • CRDL 2017
  • SBI 1992
  • Country
  • CRDL Canada
  • SBI United States
  • Employees
  • CRDL N/A
  • SBI N/A
  • Industry
  • CRDL Biotechnology: Biological Products (No Diagnostic Substances)
  • SBI Finance/Investors Services
  • Sector
  • CRDL Health Care
  • SBI Finance
  • Exchange
  • CRDL Nasdaq
  • SBI Nasdaq
  • Market Cap
  • CRDL 126.5M
  • SBI 111.4M
  • IPO Year
  • CRDL N/A
  • SBI N/A
  • Fundamental
  • Price
  • CRDL $1.09
  • SBI $7.92
  • Analyst Decision
  • CRDL Strong Buy
  • SBI
  • Analyst Count
  • CRDL 2
  • SBI 0
  • Target Price
  • CRDL $9.00
  • SBI N/A
  • AVG Volume (30 Days)
  • CRDL 749.6K
  • SBI 39.5K
  • Earning Date
  • CRDL 11-13-2025
  • SBI 01-01-0001
  • Dividend Yield
  • CRDL N/A
  • SBI 4.52%
  • EPS Growth
  • CRDL N/A
  • SBI N/A
  • EPS
  • CRDL N/A
  • SBI N/A
  • Revenue
  • CRDL N/A
  • SBI N/A
  • Revenue This Year
  • CRDL N/A
  • SBI N/A
  • Revenue Next Year
  • CRDL N/A
  • SBI N/A
  • P/E Ratio
  • CRDL N/A
  • SBI N/A
  • Revenue Growth
  • CRDL N/A
  • SBI N/A
  • 52 Week Low
  • CRDL $0.77
  • SBI $6.96
  • 52 Week High
  • CRDL $2.54
  • SBI $8.00
  • Technical
  • Relative Strength Index (RSI)
  • CRDL 44.63
  • SBI 76.54
  • Support Level
  • CRDL $1.04
  • SBI $7.63
  • Resistance Level
  • CRDL $1.10
  • SBI $7.67
  • Average True Range (ATR)
  • CRDL 0.06
  • SBI 0.05
  • MACD
  • CRDL 0.01
  • SBI 0.03
  • Stochastic Oscillator
  • CRDL 38.24
  • SBI 92.03

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

About SBI Western Asset Intermediate Muni Fund Inc

Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager. The Fund also maintains a dollar-weighted average effective maturity of between three and ten years.

Share on Social Networks: